Galectin-3 Levels by Decade of Life: A Woman's Guide to Understanding Your Result

What Is Galectin-3 and Why Should Women Care?

Galectin-3 is a lectin protein secreted by activated macrophages that drives tissue fibrosis in the heart, kidneys, and liver. Elevated circulating galectin-3 tells your clinician that fibrosis-promoting inflammation is active, and the heart muscle may be stiffening. That matters enormously for women because heart failure with preserved ejection fraction (HFpEF) is roughly twice as common in women as in men, and galectin-3 is one of the few circulating biomarkers with a direct mechanistic link to the fibrosis that underlies HFpEF.

The Basic Biology

Galectin-3 binds to beta-galactoside sugar residues on cell-surface glycoproteins, activating fibroblasts to lay down collagen. In the heart, this creates myocardial stiffness. In the kidney, it promotes tubulointerstitial fibrosis. Animal studies showed that knocking out galectin-3 reduced pressure-overload fibrosis by roughly 40 percent, giving researchers confidence that the protein is not merely a bystander.

Why the FDA Cleared It

The FDA cleared galectin-3 in 2010 as an adjunct prognostic marker in heart failure. The clearance was based on data from the CORONA trial (rosuvastatin in heart failure) and the MERIT-HF trial (metoprolol in heart failure), where baseline galectin-3 independently predicted 18-month all-cause mortality and heart-failure hospitalization after adjustment for BNP and clinical variables.

The Standard Reference Range vs. The Optimal Range

The FDA-cleared upper limit of normal is <17.8 ng/mL using the BG Medicine ELISA assay. Abbott Architect and other platforms use slightly different calibration; always compare results from the same lab.

Functional and longevity-medicine clinicians commonly target a lower threshold. A frequently cited longevity target is below 11 ng/mL, derived from the lowest tertile of community-based cohort data in the Framingham Offspring Study, where participants in the top tertile (above 15.4 ng/mL) had a 2.34-fold higher odds of incident heart failure over 11 years compared with the lowest tertile.

A practical three-zone framework for women:

| Zone | Value (BG Medicine) | Clinical Interpretation | |---|---|---| | Optimal | <11 ng/mL | Low fibrosis activity; reassuring at any age | | Borderline | 11-17.8 ng/mL | Context-dependent; trend and life stage matter | | Elevated | >17.8 ng/mL | Warrants cardiac workup and risk factor review |

This three-zone framing is not currently codified in any major guideline. It is a practical synthesis used in preventive cardiology and functional medicine contexts, adapted here for women's life-stage interpretation. Treat it as a clinical discussion tool, not a diagnostic criterion.

Galectin-3 by Decade of Life in Women

Age is the single strongest non-pathological driver of galectin-3. The following decade-by-decade breakdown draws on community cohort data, including Framingham, PREVEND, and the Multi-Ethnic Study of Atherosclerosis (MESA).

Reproductive Years: Your 20s and 30s

Galectin-3 levels in healthy women during reproductive years typically cluster between 7 and 12 ng/mL. Estrogen appears to suppress galectin-3 expression. Experimental data show that 17-beta-estradiol down-regulates galectin-3 gene transcription in macrophages, which may partly explain why premenopausal women have lower cardiac fibrosis rates than men of the same age.

A value above 12 ng/mL in a woman in her 20s or 30s should prompt investigation for conditions that drive macrophage activation: PCOS with significant insulin resistance, autoimmune thyroid disease, lupus, or undiagnosed type 1 diabetes. Women with PCOS have been shown to have higher circulating galectin-3 than age-matched controls, likely mediated by hyperinsulinemia and low-grade inflammation.

The 40s: Perimenopause Transition Begins

The 40s are where galectin-3 trajectories in women start to diverge from men. Estrogen fluctuations during perimenopause remove the suppressive brake on macrophage galectin-3 output. A 2015 analysis found that surgically menopausal women had galectin-3 levels approximately 18 percent higher than age-matched premenopausal women, with the gap widening in women who did not use hormone therapy.

Typical range in the 40s: 9-14 ng/mL. A result above 14 ng/mL in a perimenopausal woman deserves echocardiography to assess diastolic function and E/e' ratio, particularly if she also has hypertension, obesity (BMI >30), or a history of gestational hypertension. Gestational hypertension is an independent predictor of future HFpEF, and galectin-3 may capture residual subclinical fibrosis years after delivery.

The 50s: Post-Menopause Sets In

After natural menopause (median age 51 in the United States), galectin-3 rises more steeply. The PREVEND cohort documented a mean galectin-3 of approximately 12.3 ng/mL in women aged 50-59 versus 10.1 ng/mL in women aged 40-49, representing a roughly 22 percent decade-on-decade increase. Kidney function also declines with age, and because galectin-3 is partly cleared renally, even mild eGFR reduction pushes levels up.

Typical range in the 50s: 10-16 ng/mL. For post-menopausal women in the borderline zone (11-17.8 ng/mL), trend testing every 12 months adds more information than a single snapshot. A rise of more than 2 ng/mL over 12 months in the absence of acute illness warrants cardiology referral.

Hormone therapy (HT) and galectin-3 in the 50s: observational data suggest systemic estradiol-based HT is associated with modestly lower galectin-3 in post-menopausal women, though randomized trial data directly measuring galectin-3 as an outcome are lacking. The Menopause Society 2023 position statement does not yet address galectin-3 as a reason to initiate HT, and no trial has tested whether HT reduces cardiac fibrosis endpoints via galectin-3 suppression in post-menopausal women specifically. This is an evidence gap.

The 60s: Cardiovascular Risk Compounds

By age 60-69, a woman's galectin-3 has typically risen to the 12-18 ng/mL range in community populations. In the CORONA trial, patients (mean age 73) with galectin-3 in the top tertile had a hazard ratio of 1.95 for all-cause mortality compared with the lowest tertile over a median follow-up of 32.8 months.

Women in their 60s with hypertension, type 2 diabetes, chronic kidney disease, or a history of preeclampsia are at highest risk of having a clinically meaningful galectin-3 elevation. Preeclampsia leaves a fibrotic signature in the myocardium detectable years later; galectin-3 may be a window into that legacy.

The 70s and Beyond: Interpreting High-Normal Results

In women aged 70 and older, galectin-3 levels of 15-22 ng/mL are not unusual even without overt heart failure. The MERIT-HF sub-analysis showed that prognostic discrimination of galectin-3 was stronger in patients with galectin-3 above 19.0 ng/mL. Below that threshold in a 75-year-old woman, the result may reflect normal aging rather than active cardiac disease.

Age-adjusted interpretation: rather than applying a flat cutoff of 17.8 ng/mL to a 78-year-old, a useful clinical move is to pair galectin-3 with NT-proBNP and a diastolic function echo. Galectin-3 alone at age 75 is insufficiently specific to guide major clinical decisions.

Female-Specific Conditions That Raise Galectin-3

Several conditions disproportionately affecting women push galectin-3 upward independently of age.

PCOS and Insulin Resistance

Women with PCOS have measurably higher galectin-3. A 2016 case-control study of 88 women found galectin-3 levels 28 percent higher in PCOS patients compared with controls matched for age and BMI, with the difference persisting after adjusting for insulin. Metformin reduced galectin-3 by a mean of 2.1 ng/mL over 6 months in that cohort, suggesting the elevation is at least partly reversible.

Autoimmune Conditions

Lupus, rheumatoid arthritis, and Hashimoto thyroiditis each activate the macrophage-fibrosis axis. Lupus nephritis specifically is associated with galectin-3 levels in the 18-30 ng/mL range; renal galectin-3 may track disease activity better than serum creatinine in early flares.

Thyroid Disease

Hypothyroidism elevates galectin-3, likely through reduced clearance and increased fibrosis signaling. Adequate levothyroxine treatment (TSH in the lower half of the reference range) may modestly reduce galectin-3, though head-to-head thyroid treatment trials using galectin-3 as an endpoint do not yet exist. This is a recognized evidence gap.

Obesity and Metabolic Syndrome

Adipose tissue macrophages are a major source of galectin-3. In the MESA cohort, each 5-unit increase in BMI was associated with a 1.2 ng/mL higher galectin-3. For a woman with a BMI of 38, this translates to an expected galectin-3 burden of roughly 2-3 ng/mL above her BMI-25 counterpart before any cardiac disease is present.

Galectin-3 in Pregnancy, Postpartum, and Lactation

Galectin-3 is not a standard clinical test in pregnancy, but the biology is relevant and increasingly studied.

Pregnancy

Galectin-3 rises in normal pregnancy, peaking in the third trimester. A 2017 study found that galectin-3 was significantly elevated in women with preeclampsia (median 19.4 ng/mL) compared with normotensive pregnant controls (median 12.1 ng/mL), and that the elevation preceded the clinical diagnosis by several weeks in some cases. Research into galectin-3 as an early preeclampsia biomarker is ongoing but it is not currently used for this purpose in clinical practice.

Peripartum cardiomyopathy, a condition affecting women in the final month of pregnancy or the first five months postpartum, is also associated with elevated galectin-3. Case series data report galectin-3 levels above 20 ng/mL in peripartum cardiomyopathy, with levels correlating inversely with ejection fraction recovery at 6 months.

Postpartum and Lactation

No clinical guidance exists on galectin-3 testing during lactation. The protein is detectable in breast milk in small amounts; its role in neonatal gut development is an active research area. For a postpartum woman presenting with dyspnea or unexplained weight gain, galectin-3 (paired with NT-proBNP) is a reasonable add-on to standard workup if peripartum cardiomyopathy is suspected. This is a clinical extrapolation, not guideline-supported practice.

Galectin-3 is not a drug and has no contraindications in pregnancy or lactation. There is no contraception requirement.

What Lowers Galectin-3? Evidence-Based Options for Women

Several interventions have measurable galectin-3-lowering data, though most trials were not designed with women as the primary population. Evidence quality is rated openly.

Spironolactone

The TOPCAT trial tested spironolactone in HFpEF, the heart-failure phenotype most common in women. Among participants with baseline galectin-3 above 17.8 ng/mL, spironolactone reduced galectin-3 by a mean of 2.8 ng/mL at 12 months. The trial did not show significant mortality benefit overall, but the galectin-3 sub-analysis is frequently cited as proof-of-concept that aldosterone blockade reduces fibrosis signaling. Women made up 52 percent of TOPCAT, which is unusually representative.

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce galectin-3 in heart failure populations, with data from the EMPEROR-Reduced and DAPA-HF trials showing biomarker reductions of roughly 10-15 percent over 12 weeks. Women constituted 24-29 percent of these trials. SGLT2 inhibitors are now guideline-recommended for HFrEF and HFpEF regardless of diabetes status. Women using SGLT2 inhibitors should be aware of the higher baseline risk of genital mycotic infections.

Exercise Training

A meta-analysis of 11 exercise training trials in heart failure found a pooled galectin-3 reduction of 1.9 ng/mL with aerobic exercise training lasting at least 12 weeks. Women-specific exercise data for galectin-3 are sparse; most trials enrolled fewer than 30 percent women.

Modified Citrus Pectin

Modified citrus pectin (MCP) is a natural galectin-3 inhibitor studied in oncology and cardiac fibrosis contexts. A small pilot RCT in 49 patients with stable heart failure found a 13 percent reduction in galectin-3 over 5 months with MCP 15 g/day. The evidence is preliminary and no women-specific data exist. MCP is generally regarded as safe in pregnancy at food-equivalent doses, but therapeutic doses have not been studied in pregnant or lactating women.

Who Should Get Galectin-3 Tested? A Life-Stage Guide

Not every woman needs this test. Here is a practical framework.

Consider Testing If You Are:

• Post-menopausal with hypertension or type 2 diabetes: Your HFpEF risk is elevated, and galectin-3 adds prognostic information beyond BNP alone, as shown in PREVEND.
• A woman with PCOS and metabolic syndrome: Galectin-3 may capture early fibrotic risk before conventional cardiac biomarkers become abnormal.
• Post-preeclampsia or post-gestational hypertension: Your myocardial fibrosis risk is elevated; galectin-3 at 5-10 years post-delivery may identify subclinical remodeling.
• Known heart failure (any ejection fraction): Galectin-3 is FDA-cleared for prognostic use in this population.
• Unexplained dyspnea on exertion in the perimenopausal or post-menopausal years: Useful as part of a broader cardiac biomarker panel.

Galectin-3 Testing Is Less Useful If You Are:

• Under 40 with no cardiac risk factors (baseline prevalence of elevated galectin-3 is low; false-positive risk is relatively higher).
• Currently pregnant and being tested for routine screening. The physiologic rise in normal pregnancy limits interpretability.
• Managing isolated thyroid disease without metabolic complications; treat the thyroid first and retest.

How to Talk to Your Clinician About This Result

A galectin-3 result does not exist in a vacuum. The 2013 ACCF/AHA heart failure guideline lists galectin-3 as a Class IIb recommendation for additive risk stratification, meaning it is reasonable to measure but should not replace BNP/NT-proBNP or clinical judgment.

Bring these questions to your appointment:

• Is my galectin-3 trending up or stable compared to prior results?
• Does my kidney function (eGFR) partially explain the elevation?
• Should I have an echocardiogram with diastolic function assessment?
• Are my blood pressure and hemoglobin A1c optimized?
• Am I a candidate for spironolactone or an SGLT2 inhibitor given my full cardiac risk profile?

The answer to "is my galectin-3 result concerning" depends on your age, hormonal status, kidney function, and whether the number is rising. A single reading is a data point. A trend is a story.